6533b86efe1ef96bd12cbea6
RESEARCH PRODUCT
An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors.
Elmar ChristMartin SuchanKathrin KunaYasmina OuchanLena M. KranzKlaus KühlckeOliver KleinArne BillmeierÖZlem TüreciKristina MichelDavid WeberPetra OehmMatthias BirtelKatharina ReinhardThomas BukurUgur SahinBenjamin RengstlKathleen HobohmKarolina Anna MrozMustafa DikenVeronika JahndelStefan WöllNina Hayduksubject
medicine.medical_treatmentT-LymphocytesCellCancer VaccinesImmunotherapy AdoptiveMiceAntigenmedicineAnimalsHumansClaudinB cellMice Inbred BALB CVaccines SyntheticMultidisciplinaryReceptors Chimeric AntigenTight junctionChemistryRNAImmunotherapyChimeric antigen receptorMice Inbred C57BLmedicine.anatomical_structureClaudinsCancer researchRNAFemaledescription
A one-two, CAR-T cell punch Chimeric antigen receptor (CAR)–T cells have been clinically effective in killing certain hematological malignancies, but achieving long-term patient responses for solid tumors remains a challenge. Reinhard et al. describe a two-part “CARVac” strategy to overcome poor CAR-T cell stimulation and responses in vivo. They introduce the tight junction protein claudin 6 (CLDN6) as a new CAR-T cell target and designed a nanoparticulate RNA vaccine encoding a chimeric receptor directed toward CLDN6. This lipoplex RNA vaccine promotes CLDN6 expression on the surface of dendritic cells, which in turn stimulates and enhances the efficacy of CLDN6-CAR-T cells for improved tumor therapy. Science , this issue p. 446
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-07-02 | Science (New York, N.Y.) |